C3i Solutions
C3i Solutions is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 4 of 4 trials · Latest update first
C0371002 - Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-R338L) in adult male participants with moderately severe to severe hemophilia B (FIX:C≤2%) (BeneGene-2)
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
PaTH Forward: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Trial with an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults with Hypoparathyroidism
Sponsor Ascendis Pharma Bone Diseases A/S
- Start (EU)
- Latest update
- Estimated end
C4601003 - A PHASE 3, MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY, AND LOT CONSISTENCY OF A 6-VALENT OSPA-BASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS ≥5 YEARS OF AGE
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
A 40-week study comparing the efficacy and safety of once weekly IcoSema and daily insulin glargine 100 units/mL in participants with type 2 diabetes inadequately controlled on oral anti diabetic drugs. COMBINE 4
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for C3i Solutions?
The 2026-10-09 snapshot links C3i Solutions to 4 distinct CTIS trials. Recorded services include ePID Helpdesk supplier, MEDICAL ESCALATION AND UNBLINDING, medical escalation and unblinding 24/7, Safety reporting & pharmacovigilance. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for C3i Solutions?
Therapeutic-area tags are not recorded in this snapshot. Study-phase tags are not recorded. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to C3i Solutions conducted?
The linked trials record locations in 12 countries, including Germany, Italy, Greece, Poland, Sweden. These are trial locations, not confirmed office locations or countries where C3i Solutions delivered services.
What can this page tell me about C3i Solutions's trial experience?
Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 3 recorded name variants under C3i Solutions. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- C3I SOLUTIONS
- C3i Solutions
- C3i solutions